Drug Type Small molecule drug |
Synonyms HMR 4005, HMR-4005, LU-135252 |
Target |
Action antagonists |
Mechanism ETA antagonists(Endothelin receptor type A antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H22N2O6 |
InChIKeyFEJVSJIALLTFRP-LJQANCHMSA-N |
CAS Registry171714-84-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Darusentan | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Resistant hypertension | Phase 3 | United States | 01 Jun 2006 | |
Resistant hypertension | Phase 3 | Argentina | 01 Jun 2006 | |
Resistant hypertension | Phase 3 | Brazil | 01 Jun 2006 | |
Resistant hypertension | Phase 3 | Canada | 01 Jun 2006 | |
Resistant hypertension | Phase 3 | Denmark | 01 Jun 2006 | |
Resistant hypertension | Phase 3 | France | 01 Jun 2006 | |
Resistant hypertension | Phase 3 | Germany | 01 Jun 2006 | |
Resistant hypertension | Phase 3 | Italy | 01 Jun 2006 | |
Resistant hypertension | Phase 3 | Spain | 01 Jun 2006 | |
Resistant hypertension | Phase 3 | Sweden | 01 Jun 2006 |
Phase 2 | 40 | (Group 1) | raigkhvkoq(plbuvyjgbo) = tywesdokgz akgilmhqkc (svfrpfbhip, fnkaxtgxca - axivghiwrh) View more | - | 15 Aug 2014 | ||
(Group 2) | raigkhvkoq(plbuvyjgbo) = dqaumacxpo akgilmhqkc (svfrpfbhip, cgylrdvxne - mehaullkvn) View more | ||||||
Phase 3 | 849 | nfsalljvwp(pzausuhpoi) = qvktgltruc bqclkypqal (ciwntmcjiw ) View more | - | 01 Nov 2010 | |||
Placebo | nfsalljvwp(pzausuhpoi) = fibgmuulrz bqclkypqal (ciwntmcjiw ) View more |